Letermovir oral granules + Letermovir tablet + Letermovir intravenous

Phase 2Completed

3 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cytomegalovirus (CMV) Infection

Conditions

Cytomegalovirus (CMV) Infection

Trial Timeline

Aug 8, 2019 → Aug 25, 2023

NCT ID

NCT03940586

About Letermovir oral granules + Letermovir tablet + Letermovir intravenous

Letermovir oral granules + Letermovir tablet + Letermovir intravenous is a phase 2 stage product being developed by Merck for Cytomegalovirus (CMV) Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03940586. Target conditions include Cytomegalovirus (CMV) Infection.

What happened to similar drugs?

8 of 20 similar drugs in Cytomegalovirus (CMV) Infection were approved

Approved (8) Terminated (1) Active (11)

✅LetermovirMerckApproved

✅Single arm (ganciclovir and valganciclovir)RocheApproved

✅Ganciclovir + valganciclovir [Valcyte]RocheApproved

✅ValganciclovirRocheApproved

✅valganciclovir [Valcyte]RocheApproved

✅Valganciclovir + CMV hyperimmune globulin + ValganciclovirCSLApproved

✅CytogamKamadaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03940586	Phase 2	Completed	Aug 8, 2019	Aug 25, 2023	Cytomegalovirus (CMV) Infection

Competing Products

20 competing products in Cytomegalovirus (CMV) Infection

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
ASP0113 + Placebo	Astellas Pharma	Phase 2	35
ASP0113 + Placebo	Astellas Pharma	Phase 3	40
Letermovir 240 mg Oral Tablet	Merck	Phase 2	42
Letermovir tablet + Letermovir IV	Merck	Phase 3	40
Letermovir	Merck	Phase 1	36
Letermovir	Merck	Approved	43
Letermovir 480 MG [Prevymis]	Merck	Phase 2	42
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID	Merck	Phase 1	29
Ganciclovir	Merck	Pre-clinical	26
Letermovir + Placebo	Merck	Phase 3	40
Letermovir	Merck	Phase 2	35